Cannabidiol - therapeutic and legal aspects
- PMID: 33305718
- DOI: 10.1691/ph.2020.0076
Cannabidiol - therapeutic and legal aspects
Abstract
Cannabidiol (CBD) is an alkaloid present in Cannabis sativa, along with tetrahydrocannabinol (THC) and more than 100 other substances belonging to a group of compounds called cannabinoids. Whereas the legal status and medical use of Cannabis is a controversial issue in many countries, inconsistent legislation makes CBD status even more complicated. Some CBD products are legal in some countries, while banned in other countries, further compounding the confusion. In 2018, the Food and Drug Administration (FDA) approved the first CBD containing medical product, Epidiolex®, for the treatment of paediatric seizures. Currently, several clinical trials are in progress for the potential treatment of neurologic and behavioural disorders. CBD's current legal and regulatory status is a continuously evolving issue; the current review is presenting historical and present information regarding the use of CBD products worldwide.
Similar articles
-
The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.Epilepsy Behav. 2017 May;70(Pt B):288-291. doi: 10.1016/j.yebeh.2016.11.021. Epub 2017 Feb 4. Epilepsy Behav. 2017. PMID: 28169144 Review.
-
Medicinal cannabis tea contains variable doses of cannabinoids and no terpenes.Basic Clin Pharmacol Toxicol. 2024 Sep;135(3):334-344. doi: 10.1111/bcpt.14056. Epub 2024 Jul 23. Basic Clin Pharmacol Toxicol. 2024. PMID: 39044312
-
Clinicians' Guide to Cannabidiol and Hemp Oils.Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi: 10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Mayo Clin Proc. 2019. PMID: 31447137 Review.
-
Practical considerations in medical cannabis administration and dosing.Eur J Intern Med. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4. Eur J Intern Med. 2018. PMID: 29307505 Review.
-
Regulatory Status of Cannabidiol in the United States: A Perspective.Cannabis Cannabinoid Res. 2018 Sep 27;3(1):190-194. doi: 10.1089/can.2018.0030. eCollection 2018. Cannabis Cannabinoid Res. 2018. PMID: 30283822 Free PMC article.
Cited by
-
Cinnamyl-Modified Polyglycidol/Poly(ε-Caprolactone) Block Copolymer Nanocarriers for Enhanced Encapsulation and Prolonged Release of Cannabidiol.Pharmaceutics. 2023 Aug 13;15(8):2128. doi: 10.3390/pharmaceutics15082128. Pharmaceutics. 2023. PMID: 37631342 Free PMC article.
-
Pharmacotechnical and analytical preformulation studies for cannabidiol orodispersible tablets.Saudi Pharm J. 2021 Sep;29(9):1029-1042. doi: 10.1016/j.jsps.2021.07.012. Epub 2021 Jul 17. Saudi Pharm J. 2021. PMID: 34588849 Free PMC article.
-
"The Two Sides of the Same Coin"-Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained.Pharmaceutics. 2022 Feb 10;14(2):389. doi: 10.3390/pharmaceutics14020389. Pharmaceutics. 2022. PMID: 35214123 Free PMC article. Review.
-
Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson's and Alzheimer's Disease.Pharmaceuticals (Basel). 2025 Jun 13;18(6):890. doi: 10.3390/ph18060890. Pharmaceuticals (Basel). 2025. PMID: 40573285 Free PMC article. Review.
-
Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).Chem Res Toxicol. 2023 Feb 20;36(2):177-187. doi: 10.1021/acs.chemrestox.2c00259. Epub 2023 Jan 10. Chem Res Toxicol. 2023. PMID: 36626330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical